Expression, purification, and characterization of the cGMP-dependent protein kinases Iβ and II using the baculovirus system  by Pöhler, Doris et al.
FEBS 16239 FEBS Letters 374 (1995) 419425 
Expression, purification, and characterization of the cGMP-dependent 
protein kinases Ifl and II using the baculovirus system 
Doris P6hler a, Elke Butt a, Jutta MeiBner a, Stefan Mtiller b, Martin Lohse b, Ulrich Walter a, 
Suzanne M. Lohmann a, Thomas Jarchau a'* 
~Medizinisehe Universitiitsklinik, Labor fiir Klinisehe Biochemie, Josef-Schneider Str. 2, 97080 Wiirzburg, Germany 
bGenzentrum, MPl fiir Bioehemie, 82152 Martinsried, Germany 
Received 15 September 1995; revised version received 28 September 1995 
Abstract Detailed studies of differences in distinct cGMP ki- 
nase isoforms are highly dependent on expression of large 
amounts of these enzyme isoforms that are not easily purified by 
conventional methods. Here cGMP-dependent protein kinases, 
the type Ifl soluble form from human placenta, and the type II 
membrane-associated form from rat intestine, were each ex- 
pressed in a baculovirus/Sf9 cell system and purified in milligram 
amounts by affinity chromatography. The expressed recombinant 
proteins displayed characteristics like those of their native coun- 
terparts, cGK Ifl was expressed as a 76 kDa protein predomi- 
nantly found in the cytosol fraction, whereas cGK II was ex- 
pressed as an 86 kDa protein predominantly associated with the 
membrane fraction. The apparent K a and Vmx of eGMP for 
activation of cGK lfl were 0.5 pM and 3.4 Ixmoffmin/mg, and 
for eGK II were 0.04/*M and 1.8/,mol/min/mg. 
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1. Introduction 
Two major signal transduction pathways, one involving pro- 
duction of nitric oxide (NO), i.e. endothelium derived relaxing 
factor (EDRF), which stimulates soluble guanylyl cyclases, and 
the other composed of small peptide hormones uch as atrial 
natriuretic peptide (ANP) which stimulate transmembrane re-
ceptor guanylyl cyclases, elevate cGMP and activate cGMP 
regulated channels, phosphodiesterases, and kinases [1-4]. The 
vertebrate cGMP dependent protein k ases (cGK) consist of 
the soluble type I~ and Ifl isoforms, possible splice products 
derived from the same gene which differ only in about the first 
100 N-terminal amino acids, and a membrane-associated type 
II [5-8]. Whereas cGK I is found in high concentrations in 
cerebellar Purkinje cells, smooth muscle cells and human plate- 
lets [1], cGK II was initially described biochemically as a special 
membrane-associated form found in intestinal epithelium 
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[9,10]. Recent phylogenetic analysis of the cloned forms of these 
enzymes and others from Drosophila [11] suggest in fact that 
cGK types I and II derive from different ancestral kinases [7]. 
In order to facilitate structure-function a alyses of the dif- 
ferent cGMP kinase forms, the expression of large amounts of 
specific recombinant forms was undertaken. Since cGK Ia can 
be readily obtained by purification from bovine lung and has 
also recently been expressed using the baculovirus/Sf9 insect 
cell system [12], we chose to express cGK Ifl and cGK II, two 
less well-studied kinases, using this system. Our own experience 
and that of others indicated that bacterial expression of cGKs 
invariably led to insoluble and enzymatically inactive cGK I~ 
[13] and cGK Ifl and cGK II [14]. The reason for this remains 
unclear although it could be due to lack of posttranslational 
modification required for correct kinase folding. One critical 
modification may be the phosphorylation f a conserved thre- 
onine residue found in the catalytic (C) subunit (Thr-197) of 
cAMP-dependent kinase and cGMP kinases which appeared to 
be important for correct assembly of C subunit structure and 
for substrate orientation in cocrystallization studies of C sub- 
unit and a peptide of the protein kinase inhibitor PKI [15]. In 
contrast o expression i  E. coli, expression of cGK I isoforms 
in various mammalian cell types (COS-7, CHO, HEK 293) 
[16,17,18] and cGK II [7] in HEK 293 cells resulted in active 
enzyme; however, in insufficient amounts tbr p eparative work. 
It was particularly important to develop an expression sys- 
tem for cGK Ifl and cGK II to replace the conventional purifi- 
cation methods for these enyzmes, cGK Ifl has been purified 
from bovine aorta, but is, however, susceptible to proteolysis 
which converts about half of the native dimer form to an 
N-terminal truncated monomer [19]. cGK II is extremely sus- 
ceptible to proteolysis and therefore has only been successfully 
purified from intestine removed from surgically prepared pigs 
[9,10], a very elaborate source not widely available. Further- 
more the activation constants of conventionally purified cGK 
II could not be evaluated ue to the presence of bound cGMP 
as a result of the purification protocol [9,10]. Here we report 
the expression and purification of both cGK lfl and cGK II in 
active forms without bound cGMP and the analysis of their 
activation and kinetic properties in comparison to cGK I~. 
2. Experimental 
2.1. Materials 
TC 100 medium, antibiotics, amphotericin B and e-glutamine were 
obtained from Gibco/BRL, fetal calf serum from C.C.PRO, Baculo- 
Gold DNA from Dianova, DOTAP from Boehringer-Mannheim, re- 
striction enzymes from New England Biolabs, aprotinin (Trasylol) 
from Bayer, [y-32p]ATP from Amersham, [12SI]protein A from ICN, and 
P81 paper from Whatman. All cyclic nucleotides were purchased from 
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SSDI  0014-5793(95)01168-4 
420 D. P6hler et al./FEBS Letters 374 (1995) 419-425 
Biolog. Other chemicals were obtained from Sigma in analytical grade. 
Preparation of purified cGK Ic~ from bovine lung [20] and generation 
of polyclonal antibodies against cGKIfl and cGK II [14] have been 
described previously. The peptides Kemptide and VASPtide were syn- 
thezised in the laboratory of D. Palm, University of Wfirzburg, 
Germany. S19 cells were a kind gift of S. Br~iutigam, University of 
Wiirzburg, Germany, and 8-(2-aminoethyl)-amino-cAMP-Sepharose 
was a kind gift from H. De Jonge, University of Rotterdam; 
8-(6-aminohexyl)-amino-cAMP-Sepharose wa  synthesised as de- 
scribed [21]. 
2.2. Construction of reeombinant transJer vectors 
A recombinant transfer vector pVL-GK II, containing the 2286-bp 
open reading frame of rat intestinal cGK II flanked by 52 bp of the 
5'-untranslated and 652 bp of the 3'-untranslated s quence, was con- 
structed by cloning a 3.0 kb EcoRI/EcoRI fragment of cGK II cDNA 
[7] into the EcoRI site of the baculovirus transfer vector pVL1392. 
Similarly, pVL-GK Ifl containing nucleotides -62 to 3682 of human 
placenta cGK Ifl-cDNA [6] including the entire coding region (nt 1 to 
2058) was cloned as a 3.7 kb EcoRI/EcoRI fragment into pVL 1392. 
The coding sequences were properly orientated for transcription from 
the viral polyhedrin promotor as confirmed by restriction site analysis 
and dideoxy sequencing of the constructs. 
2.3. SJ9 cell culture and puroqcation of recombinant baculoviruses 
Standard methods for heterologous gene expression in the bacu- 
lovirus/Sf9 insect cell system were used [22]. SpodopteraJrugiperda (Sf9) 
cells were maintained as monolayers and in suspension cultures at 27°C 
in TC-100 insect medium supplemented with 10% fetal calf serum, 
2 mM e-glutamine, 100 U/ml penicillin, 100 ,ug/ml streptomycin and 
250 ng/ml amphotericin B. To obtain recombinant viruses, cotransfec- 
tion of St9 cells with 250 ng BaculoGold linearized baculovirus genomic 
DNA carrying a deletion in an essential gene for replication and 2.5 ¢tg 
purified recombinant transfer vector (pVL-GK II or pVL-GK Ifl) was 
performed according to instructions of the PharMingen BaculoGold 
transfection kit or using a liposome-mediated method with DOTAE 
Recombinant baculoviruses were identified by Western blot analysis of 
whole cell extracts of transfected Sf9 cells harvested 48 h post-transfec- 
tion using polyclonal antibodies raised against bacterially expressed 
cGK fusion proteins [14]. Purification of virus-encoding recombinant 
rat intestinal cGK II was carried out by plaque assay, whereas clones 
of recombinant virus encoding human placental cGK ],8 were obtained 
by three series of end-point dilution. Purified viruses were amplified and 
titered by end-point dilution before use for protein production. 
2.4. Infection and subcellular fractionation of SJ9 cells 
Suspension cultures (130 ml) of Sf9 cells in 250 ml spinner flasks 
(Techne) were seeded at a cell density of 3 x 105 cells/ml and grown with 
good aeration to a density of 2 x 106 cells/ml. Cells were collected, 
subsequently either left uninfected (control), or were infected with re- 
combinant baculovirus clones at an MOI > 10, and then added to fresh 
medium to again obtain 130 ml of suspension culture. Aliquots (10 ml) 
of these cultures were harvested at different times p.i. for determination 
of cell densities. Cells were centrifuged at 800 x g, washed 2 times with 
PBS and resuspended in 1 ml buffer A (10 mM PIPES, pH 7.4, 2 mM 
EDTA, 50 U/ml Trasylol, 0.7/tg/ml leupeptin, and 0.5/tg/ml pepstatin 
A). Cells were lysed by 30 passages through a 0.33 × 12 mm needle, and 
complete lysis was controlled by phase-contrast light microscopy. The 
lysates were adjusted to 150 mM NaC1 and centrifuged at 100,000 x g 
for 1 h. Supernatants were saved and pellets were resuspended in the 
same volume of buffer A containing 150 mM NaCI. Identical protein 
amounts of both fractions were analyzed for recombinant cGMP kinase 
by Western blots. 
2.5. Expression and purification of recombinant human plucental cGK lfl 
Sf9 cells (2 x 10 v) were seeded in a 650 ml cell culture flask, grown 
in monolayers and infected with the recombinant baculovirus cGK Ifl 
clone at an MOI > 10. At 48 h p.i. cells were harvested, washed twice 
with PBS, and resuspended in l ml of cold buffer B (30 mM Tris, pH 
7.4, 2 mM EDTA, 150 mM NaC1, 15 mM fl-mercaptoethanol, 1 mM 
IBMX, and 50 mM benzamidine). All further steps were carried out at 
4°C. Cells were homogenized by shear stress as described above and 
the lysates were centrifuged at 100,000 x g for 1 h. The supernatant was 
loaded on a chromatography column (inner diameter 9 mm) containing 
8-(2-aminoethyl)amino-cAMP-Sepharose (0.5 ml bed volume) and 
equilibrated with buffer B. After washing the column three times with 
1 ml of buffer B, bound protein was eluted in a batch procedure by 
suspension of the Sepharose matrix in 1 ml of buffer B containing 
30 mM cAMP. The eluate was dialysed three times against buffer C 
(20 mM Tris-HC1, pH 7.4, 1 mM EDTA, 100 mM NaCI, 5 mM fl- 
mercaptoethanol, and 20 U/ml Trasylol) followed by buffer C contain- 
ing 25% and subsequently 50% glycerol for storage of kinases at -20 ° C. 
Protein concentration was determined by comparison of purified ki- 
nases to standard amounts of BSA using SDS-PAGE. 
2.6. Expression and purification of recombinant rat intestinal cGK H 
The procedures for expression and purification of cGK II were the 
same as for cGK Ifl except for the following modifications. Infected Sf9 
cells expressing recombinant cGK II were harvested at 60 h p.i. and 
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Fig. 1. Time course ofcGK Ifl and cGK I1 expression i Sf9 suspension 
cultures. The relationship between the growth of uninfected and in- 
fected Sf9 suspension cultures (top) and the amount of expression of 
cGK lfl (middle) and cGK II (bottom) is shown. Suspension cultures 
of Sf9 cells were seeded with a cell density of 3 × 105 cells/ml, grown to 
2 x 106 cells/ml, and at t = 0 either left untreated ([] control) or infected 
with an MOI > 10 with baculovirus coding either for cGK Ifl ( l )  or for 
cGK II (o). At the p.i. times shown, aliquots of cultures were taken for 
determination of cell densities and the amount of expressed cGK lfl or 
cGK II detected in whole cell lysates by Western blots using ~25I-labelled 
protein A. The amounts of kinases per liter suspension culture were 
calculated from radioactivity bound to full-length (undegraded) cGKs 
compared to defined kinase tandards. 
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homogenized in buffer D (10 mM PIPES, pH 7.4, 2 mM EDTA, 250 
mM (NH4)2SO4. 300 mM sucrose, 0.5% Triton X-100, 1 mM IBMX, 
50 mM benzamidine, 50 U/ml Trasylol, 0.7/~g/ml leupeptin, and 0.5 
,ug/ml pepstatin A). The supernatant obtained after centrifugation f 
the lysate at 100,000 x g for 1 h was applied to an 8-(6-aminohex- 
yl)amino-cAMP-Sepharose column as described above. After washing 
the column with buffer B containing 600 mM NaC1, bound protein was 
batch eluted with buffer B containing 30 mM cAMP. Dialysis was 
performed as described for cGK 1,8 except that the dialysate and dialysis 
buffer contained 0.015% NP40. 
2. 7. lmmunoblots 
Samples of homogenates and cytosolic and particulate subcellular 
fractions made from Sf9 cells expressing cGK II or cGK lfl, as well as 
purified cGK II or cGK lfl, were subjected to SDS-PAGE using a 4% 
stacking gel and 8% separating el and subsequently transfered to 
nitrocellulose filters. The filters were incubated with polyclonal rabbit 
antisera raised against the cGMP kinases [14] and radiolabelled with 
[~25I]protein A. Radioactivity was localized after autoradiography and 
quantitated by ?'-counting of excised protein bands. 
2.8. In vitro kinase assay 
In vitro measurement of cGMP dependent protein kinase activity 
was measured as described [23] with minor modifications. Aliquots of 
cGK (10 or 50 ng) were incubated ina total volume of 100/A containing 
20 mM Tris-HC1 buffer, pH 7.4, 10 mM MgClz, 5 mM fl-mercaptoetha- 
nol, 0.01% (w/v) bovine serum albumin, 10 ¢tg VASPtide (RRKVSQE) 
[18,24,25] and various concentrations of cyclic nucleotides. The reac- 
tion was started by adding 50 /tM ATP containing 100 cpm/pmol 
D'-32p]ATP, incubated for 5 min at 30°C, and stopped with 100 mM 
EDTA. Kinase activity (flmol/min/mg protein) was measured in tripli- 
cates in all experiments. 
K/values, defined as the concentration f cyclic nucleotides produc- 
ing half-maximal cGK activation, were determined from plots of kinase 
phosphotransferase ctivity versus log concentration f cyclic nucleo- 
tide. For inhibitors, an apparent i hibition constant K~' was determined 
from Dixon plots of reciprocal enyzme activity (velocity) versus inhib- 
itor concentration. With the moderate concentrations of cGMP used, 
we assumed that only one site of cGK is saturated as has been reported 
for the bovine lung enzyme [26,27]. 
3. Results 
3.1. Expression of recombinant cGMP-dependent protein kinase 
type II and type Ifl in Sfl) cells 
Compared to control Sf9 cells, infected cells expressed pro- 
teins of either 86 kDa (cGK II) or 76 kDa (cGK Ifl) which were 
labeled by specific antibodies to the respective kinases on im- 
munoblots (cf. Fig. 2). Whereas uninfected control Sf9 cell 
suspension cultures showed optimal cell growth with a dou- 
bling rate of about 24 h, infection of Sf9 cells with recombinant 
baculovirus at an MOI>10 resulted in immediate arrest of cell 
growth followed by a rapid decline in cell viability which culmi- 
nated in lyses of the majority of cells by about 5 days p.i. (Fig. 
1, top). cGK Ifl protein was first detectable by immunoblots of 
infected cells between 23 and 34 h p.i. and thereafter steadily 
increased in amount (Fig. 1, middle panel). The maximal 
amount of cGK Ifl (76 kDa protein) expression in Sf9 cells at 
96 h p.i. was quantitated by comparing Sf9 total cell lysates on 
Western blots to standard amounts of recombinant cGK Ifl 
expressed in and purified from E. coil (not shown), and was 
calculated to be about 5 mg enzyme per liter (109 cells) of St9 
culture, equivalent to 10% of St9 cell protein. Note, however, 
that already at 72 h p.i., smaller bands representing possible 
cGK Ifl proteolytic products began to appear (Fig. 2, top). 
In contrast to the peak of cGK Ifl expression, that of cGK 
II detected by immunoblotting appeared much earlier at 48 h 
p.i. (Fig. 1, lower panel). The amount of Sf9-expressed cGK II, 
plat. ¢GK ] [ . J  Sf9 23h 34h 48h 59h 72b 
soloo.o ~ ~ ~ ~ 
,*--¢GK]6 
muc. cGK I! Ingl St9 23h 34h 48h $9b 72h 
~-cGKII 
Fig. 2. Immunoblots demonstrating distinct subcellular localizations of 
cGK 1,8 (upper ight) and cGK II (lower right) expressed in Sf9 cells. 
Aliquots were removed from suspension cultures at the p.i. times shown 
and cells were lysed in low ionic strength buffer. Shown are identical 
protein amounts of cytosol (C) and particulate (P) fractions obtained 
by 100,000 × g centrifugation f infected Sf9 ceils as described in section 
2.4. Arrows indicate the positions of cGK 1,8 and cGK II, respectively. 
The migration of recombinant cGK 1,8 purified from Sf9 cells in com- 
parison to the ndogenous isoform expressed in human platelets (plat.) 
is shown at the upper left. Similarly the migration of recombinant cGK 
II purified from Sf9 cells is compared to that of rat intestinal mucosa 
(muc.) at the lower left. No expression of either cGK Ifl or cGK II was 
observed in uninfected cells (Sf9 lane). 
quantitated by comparison of Sf9 lysates with a purified stand- 
ard of cGK II obtained from expression in E. coli (not shown), 
was calculated as 8 mg cGK II per liter (10 9 cells) Sf9 culture 
(~ 15% of total Sf9 cell protein). A small amount of possible 
cGK II proteolysis was detected beginning at about 48 h (Fig. 
2, bottom). 
3.2. Subcellular localization and purification of recombinant 
cGK Ifl and cGK H 
The molecular masses of recombinant cGK 113 and cGK II 
proteins expressed in and purified from Sf9 cells were similar 
to that of these kinases in homogenates of human platelets and 
rat intestinal mucosa, respectively (Fig. 2, left panels). The 
slight depression of the migration of cGK II in intestinal mu- 
cosa homogenate was not routinely observed. Also in Sf9 cells 
the two cGK forms showed a subcellular localization (Fig. 2, 
right panels) similar to that observed in ative tissue in which 
cGK I has been described mainly as a soluble enzyme and 
cGKI I  as a particulate one [3,7]. Both enzymes from Sf9 cell 
lysates were functionally active in in vitro kinase activity assays 
(data not shown). For subcellular fractionation studies, Sf9 
cells were lysed by shearing in low ionic strength buffer A, then 
the lysate was adjusted to contain 150 mM NaCI to prevent 
unspecific sticking of proteins to membranes before centrifuga- 
tion at 100,000 x g as described in section 2.4. Analysis of sol- 
uble and particulate subcellular fractions by Western blotting 
(Fig. 2) revealed that the major amount o fcGK Ifl protein was 
recovered in the supernatant fraction and only a small amount 
in the particulate cell fraction late in infection. In contrast o 
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Fig. 3. Purification of recombinant cGK Ifl and cGK II from infected 
Sf9 cells. The kinases were purified by affinity chromatography with 
elution by cAMP as the final step, as described in detail in section 2. 
Equivalent fractions of each purification step were analyzed by SDS- 
PAGE and Western blots as shown here. 
cGK Ifl localization, the majority of recombinant cGK II was 
detected in the particulate fraction f Sf9 cells and the small 
amount of soluble cGK II protein observed appeared to de- 
crease over time. 
Extraction experiments were carried out to solubilize cGK 
II protein for purification of the enzyme. However neither 
incubation of Sf9 cell homogenates with high salt concentra- 
tions (0.(~2 M NaC1), nor use of various detergents (0.1-5% 
Triton X-100, 0.4-2% laurylsucrose, 0.1 5 mM deoxycholate), 
nor a combination of both were effective in solubilization of 
cGK II (data not shown), cGK II was partially solubilized in 
an enzymatically active form and recovered in the cytosolic 
fraction by extraction of the homogenate with buffer D con- 
taining 250 mM ammonium sulfate, 300 mM sucrose and 0.5% 
Triton X-100. However, a varying amount of cGK II still sed- 
imented in the high-speed pellet (Fig. 3, bottom, lane 3) and 
could not be solubilized even after repeated extraction. 
For purification of the kinases from infected Sf9 cell cultures, 
cells were harvested at 48 h p.i. (for cGK Ifl) or 60 h p.i. (for 
cGK II). After cell lysis, cGK Ifl and solubilized cGK II were 
further purified from supernatants of 100,000 × g centrifuga- 
tion by affinity chromatography on 8-(2-aminoethyl)-amino- 
cAMP-Sepharose or 8-(6-aminohexyl)-amino-cAMP-Sepha- 
rose, respectively. The solubilized enzymes bound with high 
affinity to the columns and could be specifically and quantita- 
tively eluted in an enzymatically active form using 30 mM 
cAME After dialysis, the overall recovery for both enzymes 
Table 1 
Activation properties of recombinant cGMP-dependent protein kinase 
Ifl and II 
K~' GMP Vm~ x Hill 
(tiM) (flmol/min/mg) coefficient 
cGK lfl 0.50 _ 0.03 (4) 3.4 -+ 0.40 (3) 1.9 __ 0.07 (3) 
cGK II 0.04 _ 0.01 (6) 1.8 _+ 0.38 (6) 1.2 _+ 0.07 (6) 
Results represent the means + S.E.M. for three to six separate kinase 
assays (number in parentheses), each performed with triplicate determi- 
nations. Basal enzyme activity Cumol/min/mg) was 0.24 + 0.08 for cGK 
Ifl and 0.23 + 0.03 for cGK II. 
varied between 15% and 33% of the initial amount measureable 
in the homogenates. A minor fraction of cGK Ifl did not bind 
to the affinity matrix (Fig. 3, top, lane 4), perhaps due to 
denaturation of the enzyme, since this material was again re- 
covered in the flow-through fraction after its reapplication to 
the column. A representative Coomassie blue-stained SDS gel 
shown in Fig. 4 demonstrates that purified recombinant human 
placental cGK Ifl and rat intestinal cGK II were proteins of 
molecular masses 76 and 86 kDa, respectively. The doublet of 
cGK Ifl shown in Fig. 2 (upper right panel) may have been a 
gel artifact since it was not consistently observed (e.g. Fig. 2, 
upper left panel). The minor bands of 69 kDa and 74 kDa 
observed in Fig. 4 in the purified enzymes appear to represent 
stable degradation products ince they show immunoreactivity 
on Western blots with the respective cGMP kinase antisera 
(data not shown). 
3.3. Enzymatic haracterization of recombinant cGK lfl and 
cGK H 
Purified recombinant cGK Ifl was highly stimulatable by 
cGMP (14-fold over basal activity) and had a Ka' and Vma xfor 
cGMP using VASPtide as a substrate of 0.5/.tM and 3.4/.tmol/ 
min/mg protein, respectively (Fig. 5A, Table 1). The Ka of 
cGMP for activation of recombinant cGK Ifl (0.5/.tM) agrees 
very well with that reported for the purified native enzyme (0.4 
/.tM; [19,32]). In comparison, preparations of purified recombi- 
nant cGK II were stimulated about 8-fold by cGMP and had 
a KS and Vmax for cGMP using VASPtide as a substrate of 0.04 
/IM and 1.8 ~tmol/min/mg, respectively. The apparent Hill coef- 
ficient for cGMP activation of cGK Ifl was 1.9 and for cGK 
cGK cGK 
IB II 
kDa 
97 " 
66" - -  
57 m 
43- -  
39 - -  
Fig. 4. Comparison of purified recombinant cGK Ifl and cGK II. The 
kinase preparations purified as shown in Fig. 3 were tested for homoge- 
neity by SDS-PAGE. The Coomassie staining of 2 ~tg of each prepara- 
tion is shown in comparison to the location of protein size markers. The 
smaller bands in the kinase preparations most likely represent degrada- 
tion products ince they are recognized by the antisera of the respective 
kinases. 
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Fig. 5. Kinetic characterization f recombinant cGK Ifl and cGK II 
enzyme activity. (A) Phosphotransferase activity of purified recombi- 
nant cGK Ifl (e; 50 ng) and cGK II (A; 25 ng) in the absence and 
presence of the indicated cGMP concentrations. The data (_+ S.D.) 
shown are representative of 4 separate kinase assays, each containing 
triplicate determinations. (B) Dixon plot demonstrating competetive 
inhibition of recombinant cGK II by Rp-8-pCPT-cGMPS. Plotting 
inhibitor concentration versus the reciprocal phosphotransferase activ- 
ity (velocity, pmol/min/mg) obtained with VASPtide as substrate gave 
a similar K~' in two separate experiments. 
II was 1.2 (Table 1), suggesting strong co-operativity between 
the two cGMP-binding sites, within the enzyme monomer or 
on different subunits, for cGK Ifl only, whereas very little for 
cGK II. Determination ofmaximal enzyme activities using two 
different synthetic substrate peptides, VASPtide and Kemptide, 
showed that cGK Ifl catalysed the phosphorylation of 
VASPtide at a three times greater ate than Kemptide, whereas 
cGK II showed no preference for one substrate over the other 
(data not shown). 
The Ka' values of activation of purified recombinant cGK 
types Ifl and II by certain cGMP analogs were clearly different 
(Table 2). cGK II was considerably more sensitive to 8-substi- 
tuted cGMP derivatives than was cGK Ifl (about 40-fold for 
8-Br-eGMP and 260-fold for 8-pCPT-cGMP). The decreasing 
order of potency for stimulation of cGK II was 8-pCPT- 
cGMP > > 8-Br-cGMP > cGMP > PET-cGMP. PET-cGMP ac- 
tivated cGK II and cGK Ifl with similar potency. Although 
none of the cGMP derivatives tested were found to be specific 
activators of cGK II, 8-pCPT-cGMP stimulated cGK II 
(Ka' = 0.004 pM) much better than either cGK Ia or Ifl. 
In contrast to the Ka' values for cGMP and its analogs, those 
for cAMP and two of its derivatives, 8-Br-cAMP and Sp-5,6- 
DCI-cBiMPS, were very high for all cGMP-kinases. With 
Sp-5,6-DC1-BiMPS, a specific activator of cAMP-dependent 
protein kinase, complete activation of cGK II could not be 
achieved probably because high concentrations of the analog 
interfere with the kinase ATP binding site and thus maximal 
catalytic activity [28]. 
Furthermore, a recently developed antagonist for cGK I~, 
Rp-8-pCPT-cGMPS [29], was tested for its ability to inhibit 
cGK Ifl and II. Analysis of the plots of reciprocal enzyme 
activity versus analog concentration at different unsaturating 
concentrations of cGMP (Fig. 5B) revealed that Rp-8-pCPT- 
cGMPS is also a competitive inhibitor of purified recombinant 
cGK II (K i' = 0.5 pM), as well as cGK Ifl and Ia (Table 2). 
4. Discussion 
In this study we have shown that the baculovirus/Sf9 insect 
cell expression system could be used to produce milligram 
quantities of rat intestinal cGK II and human placental cGK 
Ifl for purification to apparent homogeneity by affinity chrom- 
atography on cAMP-Sepharose. The expression levels achieved 
ranged from 5 mg/l for cGK Ifl to 8 mg/1 for cGK II, corre- 
sponding roughly to 10-15% of total Sf9 cellular protein. This 
is a substantial improvement in comparison to the much 
smaller amounts which could be purified by conventional tech- 
niques from tissues which posed problems with proteolysis and 
availability. 
The properties of the expressed recombinant enzymes re- 
flected those of the native ones, The kinases had the appropri- 
ate molecular masses, were recognized by specific antibodies, 
and had the same subcellular distribution as their respective 
endogenous counterparts in mammalian tissues. Like cGK II 
expressed in Sf9 cells, cGK II endogenous to rat intestine pi- 
thelium or expressed from cDNA in HEK 293 cells was also 
associated with membranes [7,9]. It is not clear whether this 
characteristic subcellular localization of cGK II results from a 
Table 2 
Apparent activation constant (Ka') or inhibition constant (K~') of cyclic 
nucleotide analogs for recombinant cGK Ifl and cGK II 
Derivative cGK Ia* cGK Ifl cGK II 
K a' (,uM) 
cGMP 0.11 0.5 
8-Br-cGMP 0.01 1.0 
8-pCPT-cGMP 0.04 0.9 
Pet-cGMP 0.03 0.05 
cAMP 39 18 
8-Br-cAMP 5.8 10 
Sp-5,6-DCI-cBiMPS 10 27 
K~' CuM) 
0.04 
0.025 
0.0035 
0.06 
12 
6 
Rp-8-pCPT-cGMPS 0.5 0.6 0.5 
Rp-cAMPS 53 14 50 
Ka' and Ki' values were calculated from individual curves like those 
shown in Fig. 5 using VASPtide as substrate for cGK I and cGK II. 
The data represent means of triplicate determinations from one to three 
separate experiments. 
*The data for cGK la were obtained using purified bovine lung enzyme 
and Kemptide assubstrate [18,29]. 
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common posttranslational modification of the protein or from 
binding to a ubiquitous or homologous putative anchor protein 
in different host cell types. The availability of purified recombi- 
nant cGK II will allow us to address this question in more 
detail. Nevertheless, olubilization of cGK II from Sf9 cell 
membranes proved more difficult than had been reported for 
intestinal epithelium [9,10]. Whereas olubilization of the latter 
required a combination of 1% Triton and 0.5 M NaC1, this was 
insufficient for S19 cell membranes which required (NH4)2SO 4
and 0.5% Triton (in buffer D) reported to extract cytoskeleton- 
attached proteins [30], Cytoskeletal ttachment of native intes- 
tinal cGK II had also been suggested [10]. 
For the measurement of kinase activity we used two synthetic 
peptides, VASPtide (RRKVSKQE), previously shown to be a 
relatively specific substrate for cGK In, and Kemptide 
(LRRASLG) (latter data not shown), a peptide derived from 
pyruvate kinase having a higher affinity for cAMP-dependent 
protein kinase [31]. Our data indicated that cGK II accepted 
VASPtide and Kemptide equally well, whereas cGK Ic~ and 
cGK Ifl showed a moderate preference for VASPtide. All of the 
cGMP kinases eem to possess a similar equirement for multi- 
ple basic amino acid residues N-terminal to the phosphorylated 
residue as was deduced for cGK I0t [31]. The strong similarity 
of the primary amino acid sequence in the substrate binding 
region within the kinases' catalytic domains may partly explain 
their highly similar substrate binding properties. 
The activation of purified recombinant cGK Ifl from Sf9 cells 
by cyclic nucleotide analogs was similar to that of native cGK 
Ifl from bovine aorta smooth muscle [19,32], suggesting that Sf9 
cells are capable of expressing a correctly folded and modified 
enzyme. 
The activation constants of purified cGK II with respect to 
cGMP and its analogs were reported here for the first time. 
Although cGK II had been purified previously from intestinal 
epithelium, it could only be eluted from the affinity column with 
cGMP which is difficult o remove from the enzyme. Therefore 
enzyme activity was usually measured in membranes as auto° 
phosphorylation r phosphorylation f an endogenous intesti- 
nal epithelium substrate, p25 [9,10,33]. In our purification pro- 
tocol, cGK II could be eluted with cAMP which has a lower 
affinity than cGMP for the enzyme and can be removed by 
dialysis. In the in vitro kinase activity assay, cGK II was ex- 
temely sensitive to 8-pCPT-cGMP (K, '= 3.5 nM); however, 
10-260-fold higher concentrations of this analog could activate 
cGK Ic~ and cGK Ifl, respectively. Rp-8-pCPT-cGMPS be- 
haved as a competitive inhibitor of cGKlI, however demon- 
strated no selectivity towards this isoform since it inhibited the 
two other cGMP kinases equally well. 
The relative order of cGMP activation of specific cGMP 
kinase forms we observed (recombinant cGK II, K, = 0.04 
pM > purified cGK In, Ka = 0.1 pM > recombinant cGK Ifl 
Ka -- 0.5/.tM) agrees with the cGMP binding observed previ- 
ously (cGK II, K d = 5 nM>cGK Ic~, K d = 4 nM, 70 nM; distin- 
guished for the 2 sites>cGK Ifl, K d = 153 nM) [9,26,16]. For 
cGK II, there appears to be no cooperativity ofcGMP binding 
[9] or recombinant kinase activation, whereas there is positive 
cooperativity for both parameters for cGK In [34,35] and for 
cGMP activation of native [32] and our recombinant cGK It/. 
It remains to be shown whether activation of specific cGMP 
kinase forms by different intracellular cGMP concentrations 
might be of physiological relevance in intact cells as has been 
postulated [19,36]. A perspective given by our present results 
is that further studies can now be undertaken with the purified 
recombinant kinases characterized here, as well as mutants 
thereof, in order to test their distinct function in biological 
systems accessible, for example, to microinjection or patch 
clamp methods. 
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